Royalty Pharma plc (RPRX)
NASDAQ: RPRX · Real-Time Price · USD
26.41
+0.19 (0.72%)
Nov 21, 2024, 3:04 PM EST - Market open
Royalty Pharma Revenue
Royalty Pharma had revenue of $564.69M in the quarter ending September 30, 2024, with 5.29% growth. This brings the company's revenue in the last twelve months to $2.27B, down -2.51% year-over-year. In the year 2023, Royalty Pharma had annual revenue of $2.35B with 5.24% growth.
Revenue (ttm)
$2.27B
Revenue Growth
-2.51%
P/S Ratio
5.19
Revenue / Employee
$25,460,708
Employees
89
Market Cap
15.56B
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Molina Healthcare | 37.54B |
Tenet Healthcare | 20.97B |
Viatris | 15.05B |
ICON Public Limited Company | 8.31B |
Avantor | 6.82B |
Moderna | 5.08B |
Incyte | 4.08B |
United Therapeutics | 2.76B |
RPRX News
- 5 days ago - Undercovered Dozen: Aurora Cannabis, FREYR Battery, Royalty Pharma, Talos Energy + - Seeking Alpha
- 6 days ago - Royalty Pharma Announces Inaugural Prize for Impact in Healthcare - GlobeNewsWire
- 12 days ago - Royalty Pharma: Massive Opportunity Ahead - Seeking Alpha
- 14 days ago - Royalty Pharma to Acquire Royalty Interest in Geron's RYTELO for $125 Million - GlobeNewsWire
- 15 days ago - Royalty Pharma plc (RPRX) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 15 days ago - Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks With Over 3% Dividend Yields - Benzinga
- 15 days ago - Royalty Pharma Reports Third Quarter 2024 Results - GlobeNewsWire
- 16 days ago - Royalty Pharma and Syndax Pharmaceuticals Enter Into $350 Million Royalty Funding Agreement for Niktimvo - GlobeNewsWire